表观遗传治疗是治疗人类癌症，包括血液恶性肿瘤的新兴领域。这一类经FDA批准用于癌症治疗的治疗剂包括DNA去甲基化剂、组蛋白去乙酰化酶抑制剂、IDH1/2抑制剂、EZH2抑制剂和众多临床前目标/剂。大多数评估表观遗传治疗生物学效应的研究都专注于其对恶性细胞的直接细胞毒作用或其对修饰肿瘤细胞抗原表达的影响，使它们暴露于免疫监视机制中。然而，越来越多的证据表明表观遗传治疗也对免疫系统的发育和功能产生影响，包括自然杀伤(NK)细胞，这可以改变它们对癌细胞的反应。在本综述中，我们总结了研究不同类别表观遗传治疗对NK细胞发育和/或功能影响的文献。©作者2023。由牛津大学出版社代表白细胞生物学协会出版。版权所有。如需许可，请发送电子邮件至：journals.permissions@oup.com。

Epigenetic therapy is an emerging field in the treatment of human cancer, including hematologic malignancies. This class of FDA-approved therapeutic agents for cancer treatment includes DNA hypomethylating agents, histone deacetylase inhibitors, IDH1/2 inhibitors, EZH2 inhibitors, and numerous preclinical targets/agents. Most studies measuring the biological effects of epigenetic therapy focus their attention on either their direct cytotoxic effects on malignant cells or their effects on modifying tumor cell antigen expression, exposing them to immune surveillance mechanisms. However, a growing body of evidence suggests that epigenetic therapy also has effects on the development and function of the immune system, including natural killer (NK) cells, which can alter their response to cancer cells. In this review, we summarize the body of literature studying the effects of different classes of epigenetic therapy on the development and/or function of NK cells.© The Author(s) 2023. Published by Oxford University Press on behalf of Society for Leukocyte Biology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.